title: Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
abstract: The effects of lanthanum carbonate on MBD parameters were investigated in 59 hemodialysis patients who were taking calcium carbonate. Lanthanum carbonate (initial dosage: 750 mg/day), as a replacement for or in combination with calcium carbonate and/or sevelamer hydrochloride, was administered for 12 months with increase/decrease of dosages. Lanthanum carbonate replaced calcium carbonate for 21 cases and was co-administered in 38 cases. It replaced sevelamer hydrochloride in 20 cases and was co-administered in 10 cases. Both the number of cases to which calcium carbonate was administered and their dosages decreased to about 70-80% 12 months after the initiation, and cases administered sevelamer decreased to about 30%. In the cases for which lanthanum carbonate was co-administered, the dosages of calcium carbonate and sevelamer slightly decreased. A significant decrease in serum calcium level was observed. In the serum phosphorus levels (P levels), significant decrease compared with the initial level was observed only at six and nine months. Intact parathyroid hormone (iPTH) level remained stable at around 230 pg/mL without significant change. The dosage of vitamin D and cinacalcet remained without significant change. The results of this trial suggest that, if dosages of vitamin D and cinacalcet are adequately controlled, a switch to lanthanum carbonate and its concomitant use are effective to control the Ca and P levels without changing iPTH levels.
authors.affiliation: Dialysis Center, Kawakita General Hospital, Asagaya-kita 1-7-3, Tokyo, Japan. tshinoda@kawakita.or.jp
authors.forename: Toshio
authors.initials: T
authors.lastname: Shinoda
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Chida
authors.forename: Masao
authors.initials: M
authors.lastname: Takagi
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Ando
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Suzuki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tagawa
mesh_terms: D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000379:methods; D000069603:Sevelamer; D014807:Vitamin D / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D010281:Parathyroid Hormone; D011073:Polyamines; D014807:Vitamin D; D010758:Phosphorus; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; D002119:Calcium Carbonate; D002118:Calcium